The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
Compiling results from six previous studies, the analysis found Vectra DA scores are associated with worsening disease but didn't address clinical utility.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.